Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
27 hedge funds and large institutions have $6.17M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
23% more funds holding
Funds holding: 22 → 27 (+5)
4% more capital invested
Capital invested by funds: $5.93M → $6.17M (+$235K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$220K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$219K |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$218K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$206K |
| 5 |
ICM
Ionic Capital Management
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$315K |
| 2 |
GL
Governors Lane
New York
|
-$66.1K |
| 3 |
QGA
Q Global Advisors
Fort Worth,
Texas
|
-$50K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$13.1K |
| 5 |
AMH
Apollo Management Holdings
New York
|
-$9.81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Walleye Trading
New York
| $7K | – | – | – |
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4K | +$5.17K | +11,742 | New |
|
|
AGM
28
Alpine Global Management
New York
| $15 | +$7.33K | +16,628 | +66% |
|
|
BCM
29
Beryl Capital Management
Redondo Beach,
California
| – | -$315K | -629,999 | Closed |
|
|
QGA
30
Q Global Advisors
Fort Worth,
Texas
| – | -$50K | -100,000 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | +$44 | +100 | +9% |
|
CLDI.WS Hedge Fund Activity: Q1 2022 in Review
27 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q1 2022, worth a combined $6.17M — up 4% from $5.93M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CLDI.WS positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $220K. The largest seller was Beryl Capital Management, exiting entirely with an estimated $315K sold.
- 27 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q1 2022, up from 22 in Q4 2021.
- Funds reported $6.17M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q1 2022, up 4% quarter-over-quarter.
- 7 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q1 2022 and 2 closed out, a net change of +5 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q1 2022 was 683 Capital Management, an estimated $220K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q1 2022 was Beryl Capital Management, an estimated $315K sold.
Based on aggregated 13F filings for Q1 2022.